Prospective Validation of the OHI Index

Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorMeir Medical Center

About this trial

Hemophagocytic lymphohistiocytosis (HLH) associated with hematologic malignancies (HM-HLH) is a syndrome with an abysmal prognosis (10-30% 5 years overall survival). The investigators have recently established an improved diagnostic and prognostic index for HM-HLH, termed the Optimized HLH Inflammatory (OHI) index. The OHI index is comprised of the combined elevation of soluble CD25 (sCD25) \> 3,900 U/mL and ferritin \>1,000 ng/mL . However, the true incidence and outcomes of HLH/OHI+ in an unselected cohort are unknown, and so is the mechanism of HM-HLH.

Eligibility criteria

Qualifiers

Patients with hematologic malignancies

At least 18 years old

Disqualifiers

Prior recent treatment (chemotherapy/ other cytoreductive therapies in the last month)

Trial design

Treatments tested in this trial

  • Not listed

Trial groups

300 Participants
are grouped into 2 trial groups

Sponsors and collaborators

Meir Medical Center

Lead sponsor

Children's Hospital Medical Center, Cincinnati

Collaborator

Rabin Medical Center

Collaborator

Sheba Medical Center

Collaborator

Schneider Children's Medical Center, Israel

Collaborator